These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37457069)

  • 1. This is your brain on death: a comparative analysis of a near-death experience and subsequent 5-Methoxy-DMT experience.
    Michael P; Luke D; Robinson O
    Front Psychol; 2023; 14():1083361. PubMed ID: 37457069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DMT Models the Near-Death Experience.
    Timmermann C; Roseman L; Williams L; Erritzoe D; Martial C; Cassol H; Laureys S; Nutt D; Carhart-Harris R
    Front Psychol; 2018; 9():1424. PubMed ID: 30174629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Encounter With the Other: A Thematic and Content Analysis of DMT Experiences From a Naturalistic Field Study.
    Michael P; Luke D; Robinson O
    Front Psychol; 2021; 12():720717. PubMed ID: 34975614
    [No Abstract]   [Full Text] [Related]  

  • 4. A narrative synthesis of research with 5-MeO-DMT.
    Ermakova AO; Dunbar F; Rucker J; Johnson MW
    J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study.
    Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR
    Front Psychol; 2018; 9():2459. PubMed ID: 30574112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An encounter with the self: A thematic and content analysis of the DMT experience from a naturalistic field study.
    Michael P; Luke D; Robinson O
    Front Psychol; 2023; 14():1083356. PubMed ID: 37051610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).
    Nour MM; Evans L; Nutt D; Carhart-Harris RL
    Front Hum Neurosci; 2016; 10():269. PubMed ID: 27378878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q).
    Lawrence DW; DiBattista AP; Timmermann C
    J Psychoactive Drugs; 2024; 56(4):443-455. PubMed ID: 37428989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Power of Theta Oscillations Predicts Mystical-Type Experiences Induced by DMT in a Natural Setting.
    Tagliazucchi E; Zamberlan F; Cavanna F; de la Fuente L; Romero C; Sanz Perl Y; Pallavicini C
    Front Psychiatry; 2021; 12():720066. PubMed ID: 34803754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience.
    Lawrence DW; Carhart-Harris R; Griffiths R; Timmermann C
    Sci Rep; 2022 May; 12(1):8562. PubMed ID: 35610230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.
    Reckweg J; Mason NL; van Leeuwen C; Toennes SW; Terwey TH; Ramaekers JG
    Front Pharmacol; 2021; 12():760671. PubMed ID: 34912222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
    PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Within-subject comparison of near-death and psychedelic experiences: acute and enduring effects.
    Martial C; Carhart-Harris R; Timmermann C
    Neurosci Conscious; 2024; 2024(1):niae033. PubMed ID: 39220326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder.
    Barsuglia JP; Polanco M; Palmer R; Malcolm BJ; Kelmendi B; Calvey T
    Prog Brain Res; 2018; 242():121-158. PubMed ID: 30471678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
    Dourron HM; Nichols CD; Simonsson O; Bradley M; Carhart-Harris R; Hendricks PS
    Psychopharmacology (Berl); 2023 Dec; ():. PubMed ID: 38072874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infrequent near death experiences in severe brain injury survivors - A quantitative and qualitative study.
    Hou Y; Huang Q; Prakash R; Chaudhury S
    Ann Indian Acad Neurol; 2013 Jan; 16(1):75-81. PubMed ID: 23661968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
    Lancelotta RL; Davis AK
    J Psychoactive Drugs; 2020; 52(3):273-281. PubMed ID: 32148190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meditation-Induced Near-Death Experiences: a 3-Year Longitudinal Study.
    Van Gordon W; Shonin E; Dunn TJ; Sheffield D; Garcia-Campayo J; Griffiths MD
    Mindfulness (N Y); 2018; 9(6):1794-1806. PubMed ID: 30524512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.